An investigation into the anti-tumour properties of resveratrol against ovarian cancer using the CAM model.
Degree GrantorUniversity of Canterbury
Degree NameMaster of Science
Ovarian cancer is one of the deadliest gynaecological cancers. A key contributing factor to its high mortality rate is its non-specific symptoms and lack of early detection, which results in most patients being diagnosed with advanced stage cancer. Ovarian cancer is highly metastatic, with a unique route of dissemination that is facilitated by the movement of cancer cells through ascitic fluid, which accumulates in the peritoneal cavities of patients with advanced ovarian cancer. Cancer cells can then adhere to the peritoneum, or the surfaces of other organs, and form tumour nodules. This mode of metastasis is poorly understood, and therefore warrants further investigation.
Acquired resistance to currently available anticancer compounds is a common feature of advanced ovarian cancer, making the need for the development of alternative treatment options urgent. Resveratrol is a naturally-occurring food compound that has been shown to have some anti-cancer properties, including inhibition of angiogenesis, proliferation, and invasion, as well as induction of apoptosis. This study investigated the effects of resveratrol on several cellular processes known to contribute to cancer growth and survival using ovarian cancer tumour implants grown on chicken chorioallantoic membranes (CAMs) to mimic the growth of tumour nodules on the surface of the peritoneum during the early stages of metastasis.
This study demonstrated that using the CAM model as a proxy for the peritoneum is an appropriate model for investigation into the early stages of metastasis in the context of advanced ovarian cancer. Results also showed that treatment with 91 μg resveratrol inhibited invasion of OVCAR-8 and SKOV-3 cells into the CAM. This dose of resveratrol also led to a reduction in the number of red blood cells in SKOV-3 tumour implants, whereas 46 μg was sufficient to have a similar effect in OVCAR-8 tumour implants. Resveratrol may therefore be capable of slowing the progression of advanced ovarian cancer and warrants further in vivo study.